Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.32 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3140408 | 0.84 | CYP2D6 (0.37) | CYP2C19SMN1; SMN2CYP2D6LMNAHRH1 | |
| SCHEMBL3402837 | 0.80 | CYP2C19 (0.53) | CYP2C19SMN1; SMN2CYP2D6OPRD1KDM4E | |
| SCHEMBL9479770 | 0.80 | CYP2D6 (0.37) | CYP2C19CYP2D6LMNAHRH1MAPK1 | |
| SCHEMBL3938458 | 0.78 | CYP2C19 (0.43) | CYP2C19SMN1; SMN2CYP2D6LMNAHRH1 | |
| SCHEMBL8510683 | 0.77 | HRH1 (0.50) | CYP2C19SMN1; SMN2CYP2D6LMNAHRH1 | |
| SCHEMBL12825377 | 0.76 | HRH1 (0.56) | CYP2C19CYP2D6HRH1GABBR2GABBR1 | |
| SCHEMBL21308579 | 0.76 | AOC3 (0.42) | SMN1; SMN2CYP2D6LMNAHRH1KDM4E | |
| SCHEMBL3685590 | 0.76 | AOC3 (0.42) | SMN1; SMN2CYP2D6LMNAHRH1KDM4E | |
| SCHEMBL13513553 | 0.76 | TRPA1 (0.44) | CYP2C19SMN1; SMN2CYP2D6LMNAHRH1 | |
| SCHEMBL4762903 | 0.75 | CYP2C19 (0.42) | CYP2C19SMN1; SMN2LMNAHRH1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | FUKAMI NAOKI (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 2002-11-14 | — | — | US | disclosed |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-14 | — | — | US | disclosed |
| EP-1091760-A1 | PHARMACEUTICAL COMPOSITION CONTAINING AN ESTER OR AMIDE PLA2 INHIBITOR | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-04-18 | — | — | EP | disclosed |
| US-6110933-A | AN ENZYME INHIBITOR TREATING PANCREATITIS, HEPATITIS, CHRONIC RENAL FAILURE, ENDOTOXIN SHOCK, GRAM-NEGATIVE SEPTIC SHOCK, ARTHRITIS, RESPIRATORY DISEASE, HEART DISEASE, ALLERGIC DISEASE, THROMBOSIS, ARTERIOSCLEROSIS, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| WO-2000000220-A1 | PHARMACEUTICAL COMPOSITION CONTAINING AN ESTER OR AMIDE PLA2 INHIBITOR | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-06 | — | — | WO | disclosed |
| EP-0741697-B1 | AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE A2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-09-15 | — | — | EP | disclosed |
| EP-0854863-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997003951-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-06 | — | — | WO | disclosed |
| EP-0741697-A1 | AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE A2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995019959-A1 | AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE A2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-27 | — | — | WO | disclosed |
| US-4629586-A | Hexynyl alkanoates and organoleptic uses thereof | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1986-12-16 | — | — | US | disclosed |
| US-4539209-A | ENHANCING TROPICAL FLAVOR | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1985-09-03 | — | — | US | disclosed |
| US-4465695-A | FLAVOR, AROMA ENHANCERS FOR FOODS, VITAMINS | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1984-08-14 | — | — | US | disclosed |
| US-4416902-A | Flavoring with cyclohexenyl-beta-methyl acrolein derivatives | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1983-11-22 | — | — | US | disclosed |
| US-4404184-A | Flavoring with methyl-thio-2-methyl-2-pentenoate | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1983-09-13 | — | — | US | disclosed |
| US-4400390-A | TASTE AND FLAVOR ENHANCERS | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1983-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | CYP2C19 502/4885SMN1; SMN2 2521/4885CYP2D6 647/4885 |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | PLA2G4A, PLA2G4B, PLA2G1B | CYP2C19 617/4885SMN1; SMN2 2406/4885CYP2D6 761/4885 |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | CYP2C19 499/4885SMN1; SMN2 2331/4885CYP2D6 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.